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COPD—Cost Studies
PRP13
COSTS OF COPD IN GERMANY—RESULTS OF A
COST-OF ILLNESS STUDY
Spannheimer A1, Schlegel C1, Reitberger U1,Welsch R2,
Ruckdaeschel S3
1Kendle International Inc, Munich, Germany; 2Boehringer
Ingelheim Pharma KG, Ingelheim am Rhein, Germany; 3Pﬁzer
GmbH, Karlsruhe, Germany
OBJECTIVE: To assess the costs of COPD from the 
societal perspective in Germany. METHODS: The 1-year
resource use associated with COPD was documented ret-
rospectively for the year 2001, based on medical charts
of 321 patients selected at random and suffering from
mild, moderate, or severe COPD. Costs were assessed for
each stage of disease severity and weighted to total costs
using the relative frequency of COPD severity stages
derived from an epidemiological pre-study. RESULTS:
Annual COPD-related costs per patient and year were
€3027 from the societal perspective. Main cost drivers
were hospitalisations, accounting for 26% of total costs,
followed by medication (23%) and early retirement
(17%). Costs increased with disease severity from €2364
(mild) to €6585 (severe). Mainly, the COPD-related
expenditures for hospitalisation, nursing and for early
retirement increased with the disease severity. Forty
percent of the costs were caused by COPD exacerbations
while the other 60% were due to the basic treatment of
COPD. The average costs per exacerbation amounted to
€412. Large differences were observed between the costs
of an exacerbation, which required in-hospital treatment
and those, which could be treated in the outpatient setting
only. Following the results of our analysis, the main part
of the costs (64%) were covered by the sickness funds.
Assuming COPD prevalence rates between 3.3% and 5%,
annual costs of COPD range between €8.21 billion and
€12.44 billion from the societal perspective. CONCLU-
SION: COPD causes a signiﬁcant economic burden in
Germany. The costs are mainly determined by the disease
severity and the appearance of exacerbations, which
require hospitalisations. Thus, it is extremely important
not only for the patients’ well-being but also from an eco-
nomic point of view to prevent COPD and to identify
optimal COPD treatments, which are able to reduce
disease progression and avoid costly exacerbations.
PRP14
COST OFFSETS FROM PRESCRIPTION
COVERAGE OF AGED PERSONS WITH COPD
Stuart BC1, Doshi J1, Briesacher B1,Wrobel M2
1University of Maryland Baltimore, Baltimore, MD, USA; 2Abt
Associates, Cambridge, MA, USA
Numerous studies have shown that appropriate drug use
can reduce hospitalization and other more expensive ther-
apies. Some commentators argue that these ﬁndings imply
that drug coverage pays for itself. As appealing as this
conclusion may be, there is no credible research literature
to support it. OBJECTIVES: This study is one of a series
to assess the extent to which extending drug coverage to
all US Medicare beneﬁciaries would result in cost savings
elsewhere in the Medicare budget. Using data from the
Medicare Current Beneﬁciary Survey (1996–2000), we
assess each link in the causal chain between drug cover-
age and other health care spending for a sample of ben-
eﬁciaries diagnosed with COPD. We selected COPD for
3 reasons: it is a prevalent problem affecting about 16%
of the population over 65, acute exacerbations of the
disease are sensitive to medication therapy, and there are
reports that under-medication may be associated with
lack of prescription coverage. We compared expenditures
for COPD patients with and without drug coverage con-
trolling for selection effects and other confounders using
two METHODS: 1) A general linear regression model
with a gamma distribution and a log link function, and
2) by weighting sample observations based on propensity
scores. The propensity scores were derived from a logit
regression of prescription coverage status on a rich set of
sociodemographic variables and a medical expenditure
risk adjuster speciﬁcally designed for use with Medicare
claims. Our results indicate that for every 10% increase
in the generosity of drug coverage, drug spending rises
between 3% and 4%, while inpatiet hospital and physi-
cian spending each decline by 3% to 4%. The generaliz-
ability of these results to older people with other chronic
conditions is discussed.
RESPIRATORY DISORDERS—Clinical Outcomes
Studies
PRP15
DO RESPIRATORY DRUGS REDUCE HOSPITAL
ADMISSIONS? AN ECOLOGICAL STUDY
CARRIED OUT IN MODENA, ITALY,TO
INVESTIGATE DISTRICTS’ VARIABILITY
Maltoni S1, Marata AM1, Brunetti M1, Menna A1,Violante A1,
Fellin G2, Campomori A1, Magrini N1
1CeVEAS, Modena, Italy; 2AUSL Modena, Modena, Italy
OBJECTIVES: To verify if the variability observed in pre-
scription of respiratory drugs is related to a different 
hospital admission rate for respiratory diseases (asthma
and chronic obstructive pulmonary disease, COPD).
METHODS: We carried out an ecological study in the
Local Health Unit of Modena (632,000 inhabitants, 7
districts, 517 general practitioners—GPs- and 40 primary
care groups). Every GP, primary care group and district
receives two different reports quarterly, both weighted for
age and sex. The ﬁrst report is on drugs prescribed and
reimbursed by the National Health System (NHS) and the
second one on NHS hospital admissions. For drug con-
sumption, data are retrieved from the 157 retail pharma-
cies in Modena. The chosen indicators are per person
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expenditure and deﬁned daily doses (DDD) per 1000
inhabitants/day. Drugs are examined according to the
ATC (Anatomic Therapeutic Chemical) classiﬁcation.
The main indicator for hospital admissions is the number
of admissions per 1000 inhabitants/year. Our preliminary
analysis focused on respiratory drugs and hospital ad-
missions for asthma and COPD in Modena districts.
RESULTS: In year 2000, overall and per person expen-
diture for respiratory drugs were €6.614.098 (7.5% of
total expenditure) and €10.6, respectively. We observed
variability in drug prescription among districts: extreme
values were reported for districts of Mirandola, 44.1
DDD per 1000 inhabitants/day, and Carpi, 35.3. Asthma
and BPCO admission rates showed a broad variability as
well: 3.2 and 3.3 admissions per 1000 inhabitants/year
for Carpi and Mirandola, respectively, and 8.4 for
Pavullo. Our analysis showed no correlation between
drug prescription and hospital admission: districts with
similar admission rates (Mirandola and Carpi) reported
quite different values in drug prescription. CONCLU-
SIONS: These preliminary ﬁndings are the starting point
for more speciﬁc analyses that will explore possible deter-
minants of the observed variability in order to increase
appropriate use of drugs.
RESPIRATORY DISORDERS—Cost Studies
PRP16
COST-EFFECTIVENESS OF BUPROPION SR IN
THE TREATMENT OF TOBACCO DEPENDENCE
Wcislo J1, Slawik M2, Sas P2, Landa K1, Plisko R1,
Glogowski CA3, Gierczynski JM3
1HTA Consulting, Krakow, Malopolska, Poland; 2HTA
Consulting, Krakow, Poland; 3GlaxoSmithKline Pharmaceuticals
S.A, Warsaw, Poland
Objective: The objective of this analysis is cost-effective-
ness comparison of bupropion SR in the treatment of
tobacco dependence versus: placebo, nicotine replace-
ment therapy (NRT), bupropion SR used in combination
with NRT (BUPR+NRT). METHODS: The efﬁcacy
analysis was carried in accordance with guidelines for 
systematic review basing on credibility criteria of the
Cochrane Collaboration—Cochrane Reviewers’ Hand-
book and Evidence Based Medicine. Cost analysis
included direct costs from payer’s extended perspective
(public resources and the patient), collected in Poland.
Sensitivity analysis was performed, with consideration of
the variable costs of NRT. RESULTS: The results of meta-
analyses showed a statistically signiﬁcant increase of suc-
cessful attempts of tobacco cessation with the use of
bupropion versus placebo by 10.7% per year (ARR).
Bupropion also shows a statistically signiﬁcant superior-
ity in relation to NRT. The odds ratio of one year-long
abstinence with the use of bupropion versus NRT is 2.0
[CI 95% (1.2–3.4)]. The economic analysis has shown
that the most cost-effective is bupropion used in combi-
nation with medical advice. The cost of maintaining absti-
nence for the lifetime as a result of the use of bupropion
in combination with medical advice, calculated for one
patient, is €2,948,70; cost for LYG is €1,474,35; cost for
QALY is €1,092,23 (2002 average exchange rate: €1 =
3,86 PLN). The least favourable is NRT. The technology
being the combination of NRT and bupropion has inter-
mediate cost-effectiveness results. The cost of medical
advice has not been considered in the analysis. CON-
CLUSIONS: It may be stated that bupropion is a medic-
inal product statistically signiﬁcantly more effective
versus placebo and NRT in the treatment of nicotine
dependence. Bupropion is a cost-effective technology,
where the cost for LYG is signiﬁcantly lower than the
cost-effectiveness threshold (€10,362,69/dialysother-
apy/patient per year).
PRP17
ESTIMATING HOSPITAL BURDEN DUE TO
PNEUMONIA,ASPIRATION,AND ACUTE LUNG
FAILURE: DATA FROM THE NATIONAL
HOSPITAL DISCHARGE SURVEY (NHDS)
Caeser M1, Nichols BR2, Perfetto EM2
1ALTANA Pharma AG, Konstanz, Germany; 2The Weinberg
Group Inc, Washington, DC, USA
OBJECTIVE: Acute lung failure (ALF), often resulting
from pneumonia and/or aspiration, is associated with
high mortality. The objective of this study was to estimate
the resource burden of ALF events by characterizing
pneumonia-associated ALF using NHDS 2000 data. It
was hypothesized that using ALF diagnosis codes alone
may not capture all events; ventilation may be an impor-
tant indicator. METHODS: A base population was ed
using pre-deﬁned diagnosis codes for pneumonia and
aspiration. It was stratiﬁed using various combinations of
diagnostic and procedure groupings: pneumonia, aspira-
tion, or both; ALF; intubation and ventilation use; 
discharge status; and age. Weighting allowed for 
extrapolation to the U.S. civilian population. RESULTS:
Of the estimated 35,348,186 U.S. hospital discharges in
2000, 2,388,996 (6.8%) were associated with pneumo-
nia and/or aspiration. Of these, 192,975 (8.1%) required
ventilation, with approximately 82,840 (43%) of them
requiring ventilation for ≥96 hours. Comparatively,
278,678 (11.7%) of pneumonia and/or aspiration dis-
charges were coded as ALF; approximately 64,194 (23%)
of them required ventilation for ≥96 hours. Note that
overlap exists among these 2 subgroups (38.9% with
both ventilation and ALF), but was not extensive as
hypothesized. Of pneumonia and/or aspiration discharges
with ventilation for ≥96 hours, median length of stay
(LOS) was 19 days when discharged alive and 15 days
when discharged dead (overall median = 18 days). Of
pneumonia and/or aspiration discharges with ventilation
for <96 hours, median LOS was 8 days when discharged
alive and 4 days when discharged dead (overall median =
7 days). CONCLUSIONS: The NHDS is a useful resource
for estimating the economic burden of ALF during hos-
